Trial · NCT00563797

Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence

NCT00563797, Phase 3, Completed, Yale University; results first posted 2016-04-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence. Trials, record NCT00563797. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00563797

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
NCT number: NCT00563797
Status: Completed
Phases: Phase 3
Enrollment: 21 participants, actual
Lead sponsor: Yale University
Conditions: Alcohol Dependence, Depression
Interventions: Mecamylamine, Placebo
First posted: 2007-11-26
Last updated: 2016-04-18
Results first posted: 2016-04-18

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Drinking Days	25 weeks	Measured with time line follow back measures
Primary	Depression - Measured Using the HAMD Total Score	12 weeks	The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It should be administered by a clinician experienced in working with psychiatric patients. Although the HAM-D form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. The Scale ranges from 0 (normal) to \>23 (Very Severe Depression)
Secondary	Mean Percentage of Number of Drinking Days by Smoking Status	25 weeks	Two-way interaction between smoking and medication for percentage of drinking days captured by time line follow back surveys. Data are calculated as number of drinking days over the number of days in the study for smokers and nonsmokers receiving either mecamylamine or placebo.
Secondary	Mean Percentage of Heavy Drinking Days by Smoking	25 weeks	The two-way interaction between medication by smoking status to measure percentage of heavy drinking days measured by time line follow back survey. Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) over the number of days in the study for smokers and non smokers receiving either mecamylamine or placebo.

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Number of Drinking Days	25 weeks	days	MEAN
PRIMARY	Depression - Measured Using the HAMD Total Score	12 weeks	units on a scale	MEAN
SECONDARY	Mean Percentage of Number of Drinking Days by Smoking Status	25 weeks	Percentage of Drinking Days	MEAN
SECONDARY	Mean Percentage of Heavy Drinking Days by Smoking	25 weeks	percentage of Heavy Drinking Days	MEAN

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Drinking Days	Placebo		17.6	Standard Deviation 6.570	days
Number of Drinking Days	Mecamylamine		12.6	Standard Deviation 6.570	days
Depression - Measured Using the HAMD Total Score	Mecamylamine		8.212	Standard Deviation 1.592	units on a scale
Depression - Measured Using the HAMD Total Score	Placebo		8.10	Standard Deviation 1.60	units on a scale
Mean Percentage of Number of Drinking Days by Smoking Status	Mecamylamine	Smokers	21.34	Standard Deviation 21.96	Percentage of Drinking Days
Mean Percentage of Number of Drinking Days by Smoking Status	Placebo	Smokers	4.57	Standard Deviation 6.19	Percentage of Drinking Days
Mean Percentage of Number of Drinking Days by Smoking Status	Mecamylamine	Non-Smokers	14.76	Standard Deviation 18.63	Percentage of Drinking Days
Mean Percentage of Number of Drinking Days by Smoking Status	Placebo	Non-Smokers	48.81	Standard Deviation 35.22	Percentage of Drinking Days
Mean Percentage of Heavy Drinking Days by Smoking	Mecamylamine	Smokers	15.14	Standard Deviation 19.48	percentage of Heavy Drinking Days
Mean Percentage of Heavy Drinking Days by Smoking	Placebo	Smokers	1.68	Standard Deviation 2.47	percentage of Heavy Drinking Days

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow10

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mecamylamine	11
Overall Study	STARTED	Placebo	10
Overall Study	Received Allocated Intervention	Mecamylamine	11
Overall Study	Received Allocated Intervention	Placebo	10
Overall Study	Follow-Up	Mecamylamine	11
Overall Study	Follow-Up	Placebo	10
Overall Study	COMPLETED	Mecamylamine	4
Overall Study	COMPLETED	Placebo	8
Overall Study	NOT COMPLETED	Mecamylamine	7
Overall Study	NOT COMPLETED	Placebo	2

Source ClinicalTrials.gov

Adverse events10

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Vomiting/Diarrhea	Gastrointestinal disorders	Mecamylamine	1	11
other	Vomiting/Diarrhea	Gastrointestinal disorders	Placebo	0	10
other	Relapse to Drinking	General disorders	Mecamylamine	1	11
other	Relapse to Drinking	General disorders	Placebo	1	10
other	Worsening of Depression	Psychiatric disorders	Mecamylamine	1	11
other	Worsening of Depression	Psychiatric disorders	Placebo	0	10
other	Calcified Granuloma	General disorders	Mecamylamine	0	11
other	Calcified Granuloma	General disorders	Placebo	1	10
other	Rash	Skin and subcutaneous tissue disorders	Mecamylamine	0	11
other	Rash	Skin and subcutaneous tissue disorders	Placebo	2	10

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Mecamylamine
Total, all-cause mortality	Placebo
Total, other adverse events	Mecamylamine	3	11
Total, other adverse events	Placebo	4	10
Total, serious adverse events	Mecamylamine	0	11
Total, serious adverse events	Placebo	0	10

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Mecamylamine vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00563797

GET https://conductscience.org/api/trials/v1/NCT00563797/registered

API reference For AI assistants